

The age distribution of type-specific high-risk human papillomavirus incidence in two population-based screening trials

Running title: screen-detected hrHPV incidence

Nienke J. Veldhuijzen¹, Johannes Berkhof¹, Anna Gillio-Tos², Laura De Marco², Francesca Carozzi³,
Annarosa Del Mistro⁴, Peter J.F. Snijders⁵, Chris J.L.M Meijer⁵, Guglielmo Ronco⁶

¹ Department of Epidemiology & Biostatistics, VU University Medical Centre (VUmc), Amsterdam, the Netherlands

² Cancer Epidemiology Unit, CERMS, University of Turin, Italy

³ Cancer Prevention and Research Institute (ISPO), Florence, Italy

⁴ Veneto Institute of Oncology IOV-IRCCS, Padua, Italy

⁵ Department of Pathology, VU University Medical Centre (VUmc), Amsterdam, the Netherlands

⁶ Center for Cancer Epidemiology and Prevention, AO City of Health and Science, Turin, Italy

Corresponding author:

N.J.Veldhuijzen

VU University Medical Centre mc, Department of Epidemiology & Biostatistics

Boelelaan 1117

1081 HV Amsterdam

e-mail:n.veldhuijzen@vumc.nl

Phone: 0031-(0)20-4444935

Word count

Abstract: 250; Main text: 3.665

Tables/figures: 6

Conflict of interests

None declared

Funding

The research leading to these results has received funding from the European Community's Seventh Framework programme (FP7/2007-2013) under grant agreement No. HEALTH-F3-2013-603019 (CoheaHr)

Abstract

Background

Age- and type-specific hrHPV incidence estimates in screen-eligible women are relevant from a public health perspective because they provide an indication of the effect of vaccination on the occurrence of screen-positives in HPV-based screening. However, limited data from women over 25 years of age are available.

Methods

In 24,105 hrHPV-negative women participating in Dutch (POBASCAM) and Italian (NTCC) population-based randomized controlled screening trials the age- and type-specific distribution of incident hrHPV infections detected at the next screening round was assessed. HPV types were grouped into vaccine (bivalent: HPV16/18; polyvalent HPV16/18/31/33/45/52/58) and non-vaccine types.

Results

The incidence of screen-detected hrHPV among women aged 29-56 years was 2.54% (95% CI 2.30-2.78) in POBASCAM and 2.77% (2.36-3.19) in NTCC. In both studies, the incidence of bivalent, polyvalent, and non-polyvalent infections decreased with age (p-values < .0001). Among women with incident infection(s), vaccine-type positivity changed quadratically with age, in particular for the polyvalent vaccine (p-values: POBASCAM: bivalent 0.264, polyvalent 0.038; NTCC bivalent 0.039, polyvalent 0.005). However, over 20% and 50% of women with incident hrHPV were positive for respectively bivalent and polyvalent vaccine types in all ages in both studies.

Conclusions

We observed decreasing age trends of hrHPV vaccine and non-vaccine type incidences and age-related differences in the vaccine-type positivity among women with incident infections. Most

importantly, hrHPV infections continued to be detected in all ages and the contribution of vaccine types remained substantial.

Impact

Our results indicate a considerable reduction of new hrHPV infections in vaccinated cohorts, ensuing revision of screening guidelines

Keywords: HPV – incidence – women – screening

Introduction

Human papillomavirus (HPV) is an ubiquitous, sexually transmitted infectious pathogen with high transmission potential. Some HPV types (high-risk, hrHPV) are oncogenic and persistent infection with hrHPV is a necessary prerequisite for the development of cervical cancer. HPV types 16 and 18 are associated with about 70% of cervical cancer and HPV16 is the most common type in HPV-positive women worldwide (1, 2). A decreasing trend of hrHPV prevalence with age has been well documented among women with normal cytology in most regions of the world where organized screening programs have been implemented (1). Age- and type-specific HPV incidences are less well documented, especially not in women over 25 years of age, but provide information that is relevant from a public health perspective and that cannot be directly inferred from HPV prevalence. HPV type distribution by age in prevalent infections for example, suffer from variation in infection onset times because of differences in screening history whereas HPV type incidences do not. Type-specific incidences can therefore provide an estimate of the effect of vaccination on the occurrence of screen-positives in HPV-based screening and about the necessity of continuing screening for hrHPV-negative women beyond a certain age.

Here we report the age- and type-specific distribution of screen-detected incident hrHPV infections among participants of two large European population-based screening trials over the course of two screening rounds, including a total of 24,105 women.

Material and Methods

Studies

Data collected in the context of two population-based randomized controlled clinical trials (RCTs) evaluating the efficacy of HPV-based screening compared to cytology-based screening were included in the present analyses: the Population Based Screening Study Amsterdam (POBASCAM) and the

New Technologies for Cervical Cancer (NTCC) screening study. Both trials were conducted in the setting of regular (cytology-based) cervical cancer screening programs in the Netherlands and Italy, respectively. The designs of both trials have been previously described in detail and are only briefly outlined here (3-6).

Study populations and design

Between 1999-2002 the POBASCAM trial invited women from a well-defined area southwest of Amsterdam, attending routine cervical cancer screening visits. In the Netherlands, women become screen-eligible in the year they turn 30 years of age and are subsequently screened at 5-yearly intervals until 60 years of age. In addition, to be eligible for POBASCAM women should not have had a hysterectomy and not have a history of abnormal cytology or CIN in the last two years. Eligible, consenting women (44,102 women) were randomly assigned (1:1) to the intervention (hrHPV testing and cytology) or control group (cytology only). hrHPV testing was performed in the control group but only unblinded during data analysis.

Between 2002-2004 the NTCC trial invited women from nine areas in Italy, attending routine (3-yearly) screening visits to participate in the study. In Italy, women become screen-eligible in the year they turn 25 years of age and are subsequently screened at 3-yearly intervals until 60 years of age. In addition, to be eligible for NTCC women should not be pregnant, not have had a hysterectomy, and not been treated for CIN in the last five years. Eligible, consenting women (94,370 women) were randomly assigned (1:1) to the intervention (phase I hrHPV testing and cytology ; phase II hrHPV testing only) or control group (cytology only).

In both trials, women with borderline or mild dyskaryosis or worse (\geq ASCUS) (intervention and control arms) or who tested hrHPV positive (intervention arm only) at the baseline screening round were referred for intensified follow-up or colposcopy. All other women were advised to return for

the next screening round during which cytology and hrHPV testing was performed in POBASCAM and cytology only in NTCC. At the next screen, all hrHPV-positive samples in the intervention and control group of POBASCAM were genotyped. In NTCC, hrHPV testing and genotyping at the next screen was performed in 5 out of 9 study sites to a random sample of women in the intervention arm with baseline HPV negative results.

Laboratory testing

Only hrHPV testing and genotyping are relevant in the context of the current analyses and the procedures are described below. Other laboratory test conducted in the context of the trials were described previously (3, 7-9).

In the POBASCAM study, endocervical brush material for hrHPV testing was stored in collection medium (5 ml PBS and 0.5% thiomersal) and tested by the Department of Pathology at the VU University Medical Center. Duplicate GP5+/6+ PCR-enzyme immunoassay (EIA) followed by reverse line blot analysis (RLB) on positive samples were carried out as described previously (10). A mixture of PCR-probes was used for the detection of 14 hrHPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68).

In the NTCC study, hrHPV testing was performed on endocervical brush samples stored in PreservCyt transport medium (Cytoc Corporation, Marlborough, USA) during enrolment phase I and stored in Specimen Transport Medium during enrolment phase II and re-testing (STM, DNAPAP Cervical Sampler, Qiagen Gaithersburg, USA). Samples were tested with the Hybrid Capture 2 (HC2) hybridization assay (HC2, Qiagen Incorporated, Hilden, Germany) as previously described (7). HC2 targets 13 hrHPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). Relative light units \geq 1 pg/ml were considered positive, conform manufacturer recommendations. Genotyping by GP5+/6+ PCR and RLB was performed on HC2 positive samples including probes for the hrHPV types targeted by HC2 (10).

Statistical methods

We estimated age- and type-specific HPV incidence as the proportion positive at the first visit in second screening round for HPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68 among women who tested hrHPV-negative at baseline. Enrolment age was categorized in five-year age groups. In POBASCAM (5 year screening interval), the time window for the second round was defined as lasting from 48 to 108 months after enrolment, and in NTCC (3 year screening interval) as lasting from 24 to 60 months after enrolment.

Only baseline hrHPV negative women who had their second hrHPV test within the time window for the second screening round were included in these analyses. Women who were invited for a second screening round had an enrolment age between 29 and 56 years in POBASCAM (women aged older than 56 years at baseline are not eligible for a subsequent program screen) and 24-60 years of age in NTCC. In total POBASCAM contributed 16,671 women (n=8,254 control, n=8,417 intervention) and NTCC 7,434 women (n=2,081 enrolment phase I, n=5,353 enrolment phase II). Women who received intensified follow-up and/or referral for colposcopy based upon their enrolment HPV and/or cytology results were excluded. Consequently, eligible women had either normal cytology results (POBASCAM and NTCC phase I) or unknown cervical cytology (NTCC phase II). The intervention and control arms of the POBASCAM did not differ with respect to hrHPV incidence— and were combined. The enrolment phase I and phase II groups of the NTCC did not differ with respect to hrHPV incidence – and were combined as well.

Using a public health perspective, HPV types were grouped according to a hierarchical definition based on the inclusion of HPV types in vaccines. A woman was considered HPV16/18 positive if the HPV test was positive for at least one of the two currently vaccine-preventable high-risk types 16 and 18 (“bivalent”), and HPV16/18/31/33/45/52/58 positive (“polyvalent”) if positive for at least one of these high-risk types targeted by the investigational polyvalent vaccine (11). Consistently, non-bivalent vaccine HPV included types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and non-polyvalent vaccine

HPV included types 35, 39, 51, 56, 59 and 68. Due to multiple types infections the bivalent and non-bivalent group are not mutually exclusive, neither are the polyvalent and non-polyvalent group. In the present paper the term bivalent HPV vaccine is related to all vaccines preventing HPV 16/18 infections.

Age-stratified type-specific incidence proportions are reported with Clopper-Pearson 95% confidence intervals. To further study the relation between vaccine and non-vaccine HPV type-specific incidence and age, a logistic regression analysis was performed, including age and age squared as continuous variables, to evaluate nonlinear (quadratic) associations. Overlapping age ranges were used for these analyses, including women aged 29-56 years in POBASCAM and NTCC. In sensitivity analyses we included women of all screen-eligible ages in NTCC, aged 24-60 years. We furthermore evaluated the age-trend of the detection of vaccine and non-vaccine HPV types among women with incident infection(s) by fitting logistic regression models including vaccine or non-vaccine HPV types as dependent variable, and age, age squared and the number of new infection types as independent variables. The latter was included to account for the age-dependent clustering of infections.

The main results are reported separately for POBASCAM and NTCC. However, in the absence of heterogeneity in age-specific hrHPV incidence estimates between POBASCAM and NTCC - pooled analysis were performed as well.

Statistical analyses were done using STATA (STATA/IC 11, Stata Corp, CollegeStation, TX, USA).

Results

In total, results of 16,671 and 7,434 women were available for HPV incidence analyses in POBASCAM and NTCC respectively (Figure 1). Median age at baseline was 40 years in POBASCAM (interquartile range (IQR) 35-49 years) and 42 years in NTCC (IQR 34-51 years). Median time to the second HPV test was 5.02 years in POBASCAM (IQR 4.70-5.46) and 3.01 years in NTCC (IQR 2.98-3.11). Only 9 women

in NTCC had an interval length of more than four years, indicating minimal overlap with the intervals in POBASCAM.

POBASCAM

The overall 5-year incidence of hrHPV was 2.54% (95% CI 2.30-2.78). The most common hrHPV types among women with an incident hrHPV infection were: HPV16 (0.70% of study women); HPV31 and HPV51 (both 0.29%); HPV52 (0.26%) and HPV 56, HPV18 and HPV45 (all three 0.25%) (Table 1). The highest hrHPV incidence was found among the youngest age group (29-33 years; 5.69% (4.69-6.83)) and the lowest one among the oldest age group (54-56 years; 1.03% (0.639-1.57)) (Table 2, Figure 2). The age-associated decline of hrHPV was nonlinear and levelled off in older women (p-value quadratic term 0.016). Nonlinear declines of type-specific incidence by age were also found for vaccine-HPV types (p-value quadratic term: bivalent 0.024; polyvalent 0.002). Instead, a linear decline with increasing age was observed for non-vaccine HPV types (Table 2). The majority of incident infections were single infections (86.5%), but 11.6% included two hrHPV types and 1.90% more than two types. The proportion of women with multiple types infections declined with age (p-value (1 df) 0.007). Among women with at least one incident hrHPV infection, bivalent vaccine type infections were found in 36.4% (31.8-41.2); non-bivalent vaccine types in 71.1% (66.6-78.4); polyvalent vaccine types in 73.3% (68.8-77.4); and non-polyvalent vaccine types in 34.8% (30.2-39.5) (Table 3). The presence of polyvalent vaccine types in women with incident hrHPV infections showed a non-linear trend with age (adjusted p-value quadratic term 0.038; Table 3; Figure 3). However in all age groups, over 20% of women with incident infections had bivalent vaccine types detected and over 60% polyvalent vaccine types.

NTCC

The overall 3-year incidence of hrHPV was 3.13% (2.74-3.56) and the most common types were HPV16 (1.00%); HPV31 (0.54%); HPV51 (0.46%); HPV18 (0.41%) and HPV 56 (0.29%) (Table 1). hrHPV incidence decreased from 8.69% (6.68-10.9) in women 24-28 years of age to 0.731% (0.279-1.18) among women over 54 years of age (Table 2). Using logistic regression models, restricted to women aged 29-56 years, similar age-related trends were found as in POBASCAM. The decline in hrHPV incidence with increasing age was nonlinear for both bivalent and polyvalent vaccine types (p-value quadratic term 0.015 and 0.010 respectively), while a linear decline with increasing age was again observed for non-vaccine hrHPV types (Table 2). The majority of incident infections were single infections (78.9%) and no association of multiple infections with age was found (p-value (1 df) 0.375). When we included women aged 24-60 years, according to the screening ages in NTCC, more complicated nonlinear age-trends were observed. The decline of hrHPV overall was linear with age, but the age-trends of bivalent and polyvalent vaccine types were nonlinear. A polynomial to the fourth degree (quartic function) provided a better fit than a quadratic function (bivalent vaccine types p-value quartic term 0.015; polyvalent vaccine types 0.013).

Bivalent vaccine type infections were found in 38.6% (32.3-45.2) of women with incident hrHPV infection(s); non-bivalent vaccine types in 73.0% (66.8-78.6); polyvalent vaccine type infections in 68.7% (62.3-74.6); and non-polyvalent vaccine types in 41.2% (34.8-47.8) (Table 3). The presence of bivalent and polyvalent vaccine types in women with incident hrHPV infections showed a non-linear trend with age (adjusted p-value quadratic term 0.039 and 0.005 respectively; Table 3; Figure 3). However in all age groups, over 20% of women with incident infections had bivalent vaccine types detected and over 50% polyvalent vaccine types.

Pooled data

No statistically significant differences were found between POBASCAM and NTCC in age-stratified incidences (data not shown). All the age-related trends described above, were more pronounced and

clearly significant in the pooled dataset: restricting the population to women aged 29-56 years, the decline of incidence by age was non-linear for hrHPV overall (p-value quadratic term 0.012), for bivalent vaccine types (p-value 0.001) and for polyvalent vaccine types (p-value <0.001), but not for non-bivalent vaccine types (p-value 0.192) or non-polyvalent vaccine types (p-value 0.683). The results were similar when excluding women with multiple incident infections (p-value quadratic term hrHPV overall 0.042; bivalent vaccine types 0.006; polyvalent vaccine types 0.001; non-bivalent vaccine types 0.608; non-polyvalent vaccine types 0.129).

The presence of vaccine-types among women with (one or more) incident hrHPV infection varied with age (p-value quadratic term (adjusted for the number of infections) bivalent vaccine types 0.022; polyvalent vaccine types 0.015). Excluding women with multiple incident infections, the presence of especially polyvalent vaccine types varied with age (p-value quadratic term 0.003). The non-linear age effect was borderline significant for the presence of bivalent vaccine types (p-value quadratic term 0.056; Figure 2).

Discussion

Type-specific hrHPV incidence was estimated using data collected from two large population-based screening trials, by computing the proportion of hrHPV-negative women who tested hrHPV positive at the second screening round (i.e the point prevalence among initially hrHPV negative women). This measure corresponds to the incidence proportion during the screening interval of infections persisting until the second screen. Although the screening intervals were long (3-5 years), these incidence estimates are relevant from a public health perspective with respect to screening and vaccination – especially because the entire screen-eligible age-range is included.

Screen-detected age-specific hrHPV incidence in POBASCAM and NTCC followed a decreasing trend as has been previously described for hrHPV prevalence and incidence (1, 12, 13). The observed

decrease in hrHPV incidence by age is furthermore in line with a general decrease in the incidence of sexually transmitted diseases with increasing age, which has been explained by a decreasing number of new sexual partners per year. Natural immunity may furthermore play a role in the decline of hrHPV incidence with increasing age, although there are still many uncertainties about the level of protection naturally acquired antibodies provide and whether this effectiveness wanes over time. Remarkably, despite the different screening intervals, no substantial differences were found in the age-stratified incidence estimates from POBASCAM and NTCC. This could either be explained by a more sexually active population (more new sexual partners per year) in NTCC compared to POBASCAM, or by a fast clearance of the majority of infections early-on, after which the net result of incidence and clearance stabilizes. When screening intervals become very long the type-distribution of incident infections becomes comparable to the type distribution of prevalent infections, including more persistent types. However, we did not find a different relative proportion of vaccine- and non-vaccine HPV type infections in different durations of screening intervals in either study. Moreover, the proportion of bivalent and polyvalent vaccine types were similar between the two studies despite different re-testing interval, suggesting that the interval length we used was not long enough to lead to any difference. An interesting finding was that different age-trends were observed for the incidence of vaccine and non-vaccine HPV type. For vaccine HPV types the decline of incidence was nonlinear (quadratic) and levelled off in older ages, whereas this nonlinearity was not found for non-vaccine HPV types. We found this in the pooled study but also in the two studies separately when we used overlapping ages, from 29-56 years of age. Moreover, the presence of vaccine HPV types among all women with incident infections, significantly changed by age, following a nonlinear (quadratic) curve – also after adjusting for the number of types detected. In order to further explore confounding by multiple HPV type infections, we assessed the age- and type-specific distribution among women with an HPV incident infection with only one HPV type in the pooled dataset. The same age-related trends were observed, thereby excluding confounding by multiple infections. In contrast to the age-associated decrease in hrHPV incidence overall, these differences in the age-

related HPV type-specific distribution cannot easily be explained by sexual behaviour or by screening efforts. The latter may lead to a change in the HPV type distribution of prevalent infections but by restricting our analysis population to women with a documented negative previous HPV screening test result – we are able to focus on infections with a known time of onset and screening history is less likely to influence these results. A possible explanation might be a biological difference between HPV types. For example, protective natural immunity may be more widespread to the most common and most persisting types. Several studies, including mostly young women, have observed protective effects from naturally derived antibodies, especially for HPV16 (14-17), while a recent publication suggests differences between types (18). Another analysis among women in the placebo arm of a quadrivalent HPV vaccine study, showed direct evidence of sero-protection in younger, but not in older women (19). These type- and age-specific differences in natural immunity could explain the age-associated differences in type-specific HPV incidence. Differential re-activation of latent infections after menopause could also be an explanation.

Notwithstanding these interesting age-related distributional differences, the main findings of our study are that (1) hrHPV infections continue to be detected after a documented negative result even among older women, and (2) a substantial proportion of the newly detected hrHPV infections among older women contain vaccine hrHPV types (bivalent and polyvalent vaccine types). We cannot determine whether these infection are new infections or reactivation of previously cleared infections. These findings can be used to explore issues related to the impact of HPV vaccination of adult women (e.g. up to 39 years of age) . Clinical trials have shown that vaccine efficacy against (persistent) HPV16/18 infections among adult sexually experienced HPV DNA negative women is well over 80%, without distinguishing between (re)infection or reactivation (20). Initial vaccine efficacy estimates of a polyvalent HPV vaccine showed non-inferiority compared to the quadrivalent vaccine against persistent HPV16/18 and 96.0% vaccine efficacy against persistent HPV 31/35/45/52/58 types (21). It can thus be expected that adult vaccination will considerably reduce the burden of new hrHPV infections— especially when a polyvalent vaccine is used. Adult vaccination may then

provide an opportunity to reduce the number of screening visits in previously unvaccinated women. It should be noted that given the long time needed for progression from HPV infection to cancer (22) and given the fact that clearance of incident infections does not substantially decrease with increasing age, the risk of CIN3 and cancer in women with newly acquired hrHPV infections at older age may be low. A careful evaluation of the costs and benefits should not only take into account the hrHPV infection reduction and projected limited reductions in CIN and cancer but also cost savings from fewer screening visits.

Our analyses have some limitations. First of all, we have restricted our population to women who are screen-negative at baseline, and excluded hrHPV positive women who could have acquired a different hrHPV type during follow up. However, this allowed us to reflect upon the hrHPV incidence from a public health (screening) perspective. Screen-positive women are referred to intensified follow-up and new hrHPV types detected during follow-up will be detected after a considerable shorter time frame than our screen-detected infections. Second, when we included the youngest women (aged 24-28 years) and women over 56 years of age in NTCC, the quadratic age-related trends were no longer statistically significant, and a more complicated age-trend (polynomial to the fourth degree) provided a better explanation of the observed data. This was mainly driven by the different HPV type-specific distribution among the youngest women compared to the age-related trends found in women over 29 years of age, which could have a biological or behavioural explanation. For example, although the incidence of hrHPV overall was significantly lower in women aged 29-33 years, compared to women aged 24-28 years, the incidence of HPV16/18 did not decline. The relative contribution of HPV16/18 also had a tendency to increase from women aged 24-28 years to women aged 29-33 years. The different transmission dynamics in this youngest age group significantly influences the observed trend in other ages. A final limitation is that it must be kept in mind that these are data collected over two screening rounds among women at different ages, and not a cohort of women followed prospectively for more than two screening rounds. Therefore, we cannot exclude cohort effects. In fact, the decline in hrHPV with age could plausibly reflect a cohort

effect, as a consequence of changes in sexual behaviour. However, it is less obvious to explain the age-related differences in vaccine and non-vaccine hrHPV types by sexual behaviour or other cohort effects.

In conclusion, using data collected from two large population-based screening trials we observed decreasing trends of HPV type-specific incidences by age. The observed differences across age in the contribution of specific types in new HPV infections cannot easily be explained by sexual behavior, cohort effects or by previous screening history. Notwithstanding the reduced incidence by age, the contribution of vaccine types in new infections remained substantial. This suggests a considerable reduction of new hrHPV infections in vaccinated cohorts which demands for a revision of screening guidelines.

References

1. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. *J Infect Dis.* 2010 Dec 15;202:1789-99.
2. de Sanjose S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. *Eur J Cancer.* 2013 Nov 49:3450-61.
3. Bulkman NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. *Int J Cancer.* 2004 May 20;110:94-101.
4. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkman NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. *Lancet Oncol.* 2012 Jan;13:78-88.
5. Carozzi F, Ronco G, Gillio-Tos A, De Marco L, Del Mistro A, Girlando S, et al. Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study. *Eur J Cancer.* 2012 Jul;48:1633-7.
6. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. *Lancet Oncol.* 2010 Mar;11:249-57.
7. Ronco G, Brezzi S, Carozzi F, Dalla Palma P, Giorgi-Rossi P, Minucci D, et al. The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment. *Gynecol Oncol.* 2007 Oct;107:S230-2.
8. Gillio-Tos A, De Marco L, Carozzi FM, Del Mistro A, Girlando S, Burrone E, et al. Clinical Impact of the Analytical Specificity of the Hybrid Capture 2 Test: Data from the New Technologies for

Cervical Cancer (NTCC) Study. *J Clin Microbiol.* 2013 Sep;51:2901-7.

9. Bulkman NW, Berkhof J, Bulk S, Bleeker MC, van Kemenade FJ, Rozendaal L, et al. High-risk HPV type-specific clearance rates in cervical screening. *Br J Cancer.* 2007 May 7;96:1419-24.
10. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. *J Clin Microbiol.* 2002 Mar;40:779-87.
11. Merck. Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001 AM3; NCT00543543). [cited 2013 4 december]; Available from: <http://clinicaltrials.gov/show/NCT00543543>.
12. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. *Cancer Res.* 2008 Nov 1;68:8813-24.
13. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. *J Infect Dis.* 2005 Jun 1;191:1808-16.
14. Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. *J Natl Cancer Inst.* Nov 3;102:1653-62.
15. Ho GY, Studentsov Y, Hall CB, Bierman R, Beardsley L, Lempa M, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. *J Infect Dis.* 2002 Sep 15;186:737-42.
16. Castellsague X, Naud P, Chow SN, Wheeler CM, Gernar MJ, Lehtinen M, et al. Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA. *J Infect Dis.* 2014 Apr 3.
17. Malik ZA, Hailpern SM, Burk RD. Persistent antibodies to HPV virus-like particles following

natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. *Viral Immunol.* 2009 Dec;22:445-9.

18. Wilson L, Pawlita M, Castle PE, Waterboer T, Sahasrabudde V, Gravitt PE, et al. Seroprevalence of 8 Oncogenic Human Papillomavirus Genotypes and Acquired Immunity Against Reinfection. *J Infect Dis.* 2014 Apr 1 [Epub ahead of print].
19. Velicer C, Zhu X, Vuocolo S, Liaw KL, Saah A. Prevalence and incidence of HPV genital infection in women. *Sex Transm Dis.* 2009 Nov;36:696-703.
20. Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonog J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. *Br J Cancer.* 2011 Jun 28;105:28-37.
21. Joura EA, editor. Efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16- to 26-year old women (SS 8-4). EUROGIN; 2013 November 3-6, 2013; Florence, Italy.
22. Plummer M, Peto J, Franceschi S. Time since first sexual intercourse and the risk of cervical cancer. *Int J Cancer.* 2012 Jun 1;130:2638-44.

Table 1: Screen-detected type-specific hrHPV incidence

	hrHPV (%)	HPV16 (%)	HPV18 (%)	HPV31 (%)	HPV33 (%)	HPV35 (%)	HPV39 (%)	HPV45 (%)	HPV51 (%)	HPV52 (%)	HPV56 (%)	HPV58 (%)	HPV59 (%)	HPV68 (%)
POBASCAM	423	117	41	48	27	24	22	41	48	43	42	22	17	5
(n=16,671)	(2.54)	(0.70)	(0.25)	(0.29)	(0.16)	(0.14)	(0.13)	(0.25)	(0.29)	(0.26)	(0.25)	(0.13)	(0.10)	(0.03)
NTCC (n=7,434)	233	67	28	37	8	4	16	14	31	16	20	14	14	15
	(3.13)	(0.90)	(0.38)	(0.50)	(0.11)	(0.05)	(0.22)	(0.19)	(0.42)	(0.22)	(0.27)	(0.19)	(0.19)	(0.20)

Screenings interval POBASCAM 5 years; NTCC 3 years

Table 2: Age-specific incidence of hrHPV, (non-)bivalent vaccine types and (non-)polyvalent vaccine types

age	At risk	hrHPV		Bivalent vaccine types ⁴		Non-bivalent vaccine types ⁵		Polyvalent vaccine types ⁶		Non-polyvalent vaccine types ⁷	
	n	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)
POBASCAM											
29-33	1,899	108	5.69 (4.69-6.83)	44	2.32 (1.67-3.10)	77	4.05 (3.22-5.04)	88	4.63 (3.73-5.68)	34	1.79 (1.24-2.49)
34-38	3,671	125	3.41 (2.84-4.04)	48	1.31 (0.97-1.73)	89	2.42 (1.95-2.98)	94	2.56 (2.07-3.12)	45	1.23 (0.90-1.64)
39-43	3,251	68	2.09 (1.63-2.64)	25	0.77 (0.50-1.13)	47	1.46 (1.06-1.92)	47	1.45 (1.06-1.92)	24	0.74 (0.48-1.10)
44-48	3,174	56	1.76 (1.34-2.29)	13	0.41 (0.22-0.70)	45	1.42 (1.04-1.89)	34	1.07 (0.74-1.49)	24	0.76 (0.49-1.12)
49-53	2,639	45	1.71 (1.25-2.28)	16	0.61 (0.35-0.93)	30	1.14 (0.77-1.62)	31	1.17 (0.80-1.66)	15	0.57 (0.32-0.94)
54-56	2,037	21	1.03 (0.64-1.57)	8	0.39 (0.17-0.77)	13	0.64 (0.34-1.09)	16	0.79 (0.45-1.27)	5	0.25 (0.08-0.57)
<i>Total</i>	<i>16,671</i>	<i>423</i>	<i>2.54 (2.30-2.78)</i>	<i>154</i>	<i>0.92 (0.78-1.08)</i>	<i>301</i>	<i>1.81 (1.61-2.02)</i>	<i>310</i>	<i>1.86 (1.66-2.08)</i>	<i>147</i>	<i>0.88 (0.75-1.04)</i>
Linear effect:			<i>-0.066 (0.007)**</i>		<i>-0.079 (0.012)**</i>		<i>-0.068 (0.008)**</i>		<i>-0.076 (0.008)**</i>		<i>-0.063 (0.012)**</i>
regression coefficient											
(SE) ¹											
Nonlinear effect:			<i>0.002 (<0.001)*</i>		<i>0.003 (0.001)*</i>		<i>0.001 (0.001)</i>		<i>0.003 (0.001)*</i>		<i><0.001 (0.002)</i>
regression coefficient											

(SE)²

NTCC											
24-28	748	65	8.69 (6.77-10.94)	26	3.48 (2.28-5.05)	47	6.28 (4.65-8.27)	46	6.15 (4.54-8.12)	28	3.74 (2.5-5.36)
29-33	961	53	5.52 (4.16-7.15)	28	2.91 (1.94-4.18)	32	3.33 (2.29-4.67)	44	4.58 (3.35-6.1; 44)	15	1.56 (0.88-2.56)
34-38	1222	40	3.27 (2.35-4.43)	10	0.82 (0.39-1.5)	23	2.62 (1.8-3.68)	27	2.21 (1.46-3.2; 27)	18	1.47 (0.88-2.32)
39-43	1123	29	2.58 (1.74-3.69)	10	0.89 (0.43-1.63)	23	2.05 (1.3-3.06)	15	1.34 (0.75-2.19; 15)	15	1.34 (0.75-2.19)
44-48	1112	24	2.16 (1.39-3.19)	8	0.72 (0.31-1.41)	18	1.62 (0.96-2.55)	12	1.08 (0.56-1.88; 12)	12	1.08 (0.56-1.88)
49-53	901	12	1.33 (0.69-2.31)	4	0.44 (0.12-1.13)	10	1.11 (0.53-2.03)	8	0.89 (0.38-1.74; 8)	4	0.44 (0.12-1.13)
54-56	667	8	1.2 (0.52-2.35)	4	0.6 (0.16-1.53)	6	0.9 (0.33-1.95)	7	1.05 (0.42-2.15; 7)	3	0.45 (0.09-1.31)
57-60	700	2	0.29 (0.03-1.03)	0	0 (0-0.53)	2	0.29 (0.03-1.03)	1	0.14 (0-0.79; 1)	1	0.14 (0-0.79)
<i>Total</i>	<i>7434</i>	<i>233</i>	<i>3.13 (2.75-3.56)</i>	<i>90</i>	<i>1.21 (0.97-1.49)</i>	<i>170</i>	<i>2.29 (1.96-2.65)</i>	<i>160</i>	<i>2.15 (1.83-2.51; 160)</i>	<i>96</i>	<i>1.29 (1.05-1.57)</i>
Linear effect:			<i>-0.068 (0.011)**</i>		<i>-0.083 (0.018)**</i>		<i>-0.057 (0.012)**</i>		<i>-0.084 (0.014)**</i>		<i>-0.049 (0.016)*</i>
regression coefficient											
(SE) ^{1,3}											
Nonlinear effect:			<i>0.001 (0.001)</i>		<i>0.005 (0.002)*</i>		<i><0.001 (0.002)</i>		<i>0.004 (0.002)*</i>		<i>-0.002 (0.002)</i>
regression coefficient											

(SE)^{2,3}

¹ regression coefficient and standard error of the linear term in logistic regression models, including age as continuous variable; ² regression coefficient and standard error of the nonlinear (quadratic) term in logistic regression models, including age and age squared as continuous variable; ³ restricted to the same age range as POBASCAM (29-56 years); ⁴Bivalent vaccine types includes HPV types 16 and 18; ⁵Non-bivalent vaccine types includes HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68; ⁶Polyvalent vaccine types includes HPV types 16, 18, 31, 33, 45, 52 and 58; ⁷Non-polyvalent vaccine types includes HPV types 35, 39, 51, 56, 59 and 68. The classification in HPV types is not mutually exclusive and totals of bivalent + non-bivalent and polyvalent + non-polyvalent types exceed the 100% as a result of multiple type infections. SE stands for standard error. * p-value<0.05; ** p-value<0.001

Table 3: HPV (non-) vaccine type positivity among women with incident hrHPV infections

age- group	hrHPV positive	Bivalent vaccine types ⁴		Non-bivalent vaccine types ⁵		Polyvalent vaccine types ⁶		Non-polyvalent vaccine types ⁷	
	n	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)
POBASCAM									
29-33	108	44	40.7 (31.4-50.6)	77	71.3 (61.8-79.6)	88	81.5 (72.9-88.3)	34	31.4 (22.9-41.1)
34-38	125	48	38.4 (29.8-47.5)	89	71.2 (62.4-78.9)	94	75.2 (66.7-82.5)	45	36.0 (27.6-45.1)
39-43	68	25	36.8 (25.4-49.3)	47	69.1 (56.7-79.8)	47	69.1 (56.7-79.8)	24	35.3 (24.1-47.8)
44-48	56	13	23.2 (13.0-36.4)	45	80.4 (67.6-89.8)	34	60.7 (46.8-73.5)	24	42.3 (29.7-56.8)
49-53	45	16	35.6 (21.9-51.2)	30	66.7 (51.0-80.0)	31	68.9 (53.4-81.8)	15	33.3 (20.0-49.0)
54-56	21	8	38.1 (18.1-61.6)	13	61.9 (38.4-81.9)	16	76.2 (52.8-91.8)	5	23.8 (8.2-47.2)
<i>Total</i>	<i>423</i>	<i>154</i>	<i>36.4 (31.8-41.2)</i>	<i>301</i>	<i>71.1 (66.6-78.4)</i>	<i>310</i>	<i>73.3 (68.8-77.4)</i>	<i>147</i>	<i>34.8 (30.2-39.3)</i>
Linear effect: regression coefficient (SE) ¹			-0.011 (0.014)	0.004 (0.015)		-0.025 (0.147)		0.014 (0.014)	
Nonlinear effect: regression coefficient (SE) ²			0.002 (0.002)	-0.002 (0.002)		0.004 (0.002)*		-0.003 (0.002)	

NTCC									
24-28	65	26	40.0 (28.0-52.9)	47	72.3 (59.8-82.7)	46	70.8 (58.2-81.4)	28	43.1 (30.8-56.0)
29-33	53	28	52.8 (38.6-66.7)	32	60.4 (46.0-73.5)	44	83.0 (70.2-91.9)	15	28.3 (16.8-42.3)
34-38	40	10	25.0 (12.7-41.2)	23	80.0 (64.4-90.9)	27	67.5 (50.9-81.4)	18	45.0 (29.3-61.5)
39-43	29	10	34.5 (17.9-54.3)	23	79.3 (60.3-92.0)	15	51.7 (32.5-70.6)	15	51.7 (32.5-70.6)
44-48	24	8	33.3 (15.6-55.3)	18	75.0 (53.3-90.2)	12	50 (29.1-70.9)	12	50.0 (29.1-70.9)
49-53	12	4	33.3 (9.9-65.1)	10	83.3 (51.6-97.9)	8	66.7 (34.9-90.1)	4	33.3 (9.9-65.1)
54-56	8	4	50.0 (15.7-84.3)	6	75.0 (34.9-96.8)	7	87.5 (47.3-99.7)	3	37.5 (8.5-75.5)
57-60	2	0	0	2	100.0 (0.16-100.0)	1	50.0 (1.26-98.7)	1	50.0 (1.3-98.7)
<i>Total</i>	<i>233</i>	<i>90</i>	<i>38.6 (32.3-45.2)</i>	<i>170</i>	<i>73.0 (66.8-78.6)</i>	<i>160</i>	<i>68.7 (62.3-74.6)</i>	<i>96</i>	<i>41.2 (34.8-47.8)</i>
Linear effect: regression coefficient (SE) ^{1,3}			-0.022 (0.229)	0.043 (0.025)		-0.046 (0.024)		0.030 (0.021)	
Nonlinear effect: regression coefficient (SE) ^{2,3}			0.006 (0.030)*	-0.004 (0.003)		0.010 (0.004)*		-0.005 (0.003)	

¹ regression coefficient and standard error of the linear term in logistic regression models, including age as continuous variable and adjusted for the number of infections; ² regression coefficient and standard error of the nonlinear (quadratic) term in logistic regression models, including age and age squared as continuous variable and adjusted for the number of infections; ³ restricted to the same age range as POBASCAM (29-56 years); ⁴ Bivalent vaccine types includes HPV types 16 and 18; ⁵ Non-bivalent vaccine types includes HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68; ⁶ Polyvalent vaccine types includes HPV types 16, 18, 31, 33, 45, 52 and 58; ⁷ Non-polyvalent vaccine types includes HPV types 35, 39, 51, 56, 59 and 68. The classification in HPV types is not mutually exclusive and totals of bivalent + non-bivalent and polyvalent + non-polyvalent types exceed the 100% as a result of multiple type infections. SE stands for standard error. * p-value<0.05, ** p<0.001

Legends of figures:

Figure 1: Flow diagram of the analytical population


Figure 2: The incidence of screen-detected hrHPV

Incidence is defined as the proportion of women HPV-negative at baseline who was positive at the second screening round (POBASCAM median interval 5.0 years [interquartile range (IQR) 4.7-5.5]; NTCC median interval 3.0 years [IQR 3.0-3.1]). In POBASCAM women with an enrolment age between 29-56 years were eligible, in NTCC women with an enrolment age between 24-60 years. hrHPV types include HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.


Figure 3: HPV vaccine-type positivity among women with single hrHPV incident infection

Pooled data from POBASCAM and NTCC. Bivalent vaccine types include HPV types 16 and 18. Polyvalent vaccine types include HPV types 16, 18, 31, 33, 45, 52 and 58. Solid (black) lines: the observed incidence (95% confidence intervals) ; dashed (blue) lines: predicted values from logistic regression. P-value of the quadratic term (adjusted for the number of infections) was 0.056 for bivalent types and 0.003 for polyvalent types.

Figure 1




Author Manuscript Published OnlineFirst on October 9, 2014; DOI: 10.1158/1055-9965.EPI-14-0628
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.





Author Manuscript Published OnlineFirst on October 9, 2014; DOI: 10.1158/1055-9965.EPI-14-0628
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

bivalent vaccine types



polyvalent vaccine types



Cancer Epidemiology, Biomarkers & Prevention

AACR American Association
for Cancer Research

The age distribution of type-specific high-risk human papillomavirus incidence in two population-based screening trials

Nienke J. Veldhuijzen, Johannes Berkhof, Anna Gillio-Tos, et al.

Cancer Epidemiol Biomarkers Prev Published OnlineFirst October 9, 2014.

Updated version	Access the most recent version of this article at: doi: 10.1158/1055-9965.EPI-14-0628
Author Manuscript	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, use this link http://cebp.aacrjournals.org/content/early/2014/10/09/1055-9965.EPI-14-0628 . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.